	STA Pharmaceutical, a WuXi AppTec group company, and biopharma company Regulus Therapeutics, 

 on Feb. 22, 2018 that they have entered into a collaboration focusing on the research and mid-scale non-GMP/cGMP manufacturing of oligonucleotides.

	Under the agreement, STA will become the development and manufacturing partner for Regulus' preclinical and clinical programs of microRNA-targeting drugs used to treat a broad range of diseases. Regulus will provide STA with expertise, technical know-how, and training in the field of oligonucleotide scale-up.

	STA recently established oligonucleotide R&D labs at both its facilities in San Diego, California and Changzhou, China. The state-of-the-art oligonucleotide GMP manufacturing facility at Changzhou will become operational later in 2018.

Manufacturing

News

Supplier News

The agreement follows the recent opening of WuXi STA's oligonucleotide R&D labs in China and the US.